1 The initial discovery of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in 2008 signaled a new era in the field of glioblastoma therapy, offering novel therapeutic prospects: 2-4 Hypermethylation of the MGMT promoter has been demonstrated to be associated with significantly prolonged survival in patients who receive adjuvant radio-chemotherapy with temozolomide according to the EORTC/NCIC protocol. 5 Besides the addition of adjuvant tumor treating field therapy, till date, no significant progresses in glioblastoma therapy have been made. 1 The gene discussed is MGMT; the disease is neoplasm.